Cargando…
Variability of cost trajectories over the last year of life in patients with advanced breast cancer in the Netherlands
OBJECTIVE: In breast cancer patients, treatment at the end of life accounts for a major share of medical spending. However, little is known about the variability of cost trajectories between patients. This study aims to identify underlying latent groups of advanced breast cancer patients with simila...
Autores principales: | Schneider, Paul P., Pouwels, Xavier G. L. V., Passos, Valéria Lima, Ramaekers, Bram L. T., Geurts, Sandra M. E., Ibragimova, Khava I. E., de Boer, Maaike, Erdkamp, Frans, Vriens, Birgit E. P. J., van de Wouw, Agnes J., den Boer, Marien O., Pepels, Manon J., Tjan-Heijnen, Vivianne C. G., Joore, Manuela A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145011/ https://www.ncbi.nlm.nih.gov/pubmed/32271794 http://dx.doi.org/10.1371/journal.pone.0230909 |
Ejemplares similares
-
Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands
por: Schneider, Paul Peter, et al.
Publicado: (2021) -
Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry
por: Ibragimova, Khava I. E., et al.
Publicado: (2021) -
Healthcare Use during the Last Six Months of Life in Patients with Advanced Breast Cancer
por: Schmitz, Renée. S. J. M., et al.
Publicado: (2021) -
Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium
por: Seferina, Shanly C., et al.
Publicado: (2017) -
The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2− advanced breast cancer patients: A study of the Dutch SONABRE Registry
por: Meegdes, Marissa, et al.
Publicado: (2021)